UBS raised the firm’s price target on Akero Therapeutics (AKRO) to $109 from $42 and keeps a Buy rating on the shares. Akero reported “strong” ...

Fintel reports that on January 30, 2025, B of A Securities upgraded their outlook for Akero Therapeutics (NasdaqGS:AKRO) from ...

Sage Therapeutics was in focus after it rejected Biogen's acquisition proposal. Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow ...

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan ...

San Francsiscan liver specialist 89bio (Nasdaq: ETNB) has secured $250 million through a public stock offering, following a ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...